RxDoctor Payments Data

David Lindley, MD

Family Medicine · North Platte, NENPI 1841373032

Payments from drug & device makers

$1,068in general payments, 2019–2025

Across 8 payments — averaging $133.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Welch Allyn$788
  • Amgen$188
  • AstraZeneca$38
  • Johnson & Johnson$36
  • AbbVie$19

What the payments were for

  • Consulting fees$17516%
  • Food & beverage$10610%
  • Gifts$78874%

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Welch Allyn1$788
Amgen2$188
AstraZeneca2$38
Johnson & Johnson2$36
AbbVie1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,068 in reported general payments places this provider in the 60th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$236,098
Medicare patients
381
Services billed
11,741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide128$115,125
EliquisApixaban174$82,632
JanuviaSitagliptin Phosphate104$70,812
XareltoRivaroxaban80$43,290
JardianceEmpagliflozin49$32,685
Tresiba Flextouch U-100Insulin Degludec46$27,185
Breo ElliptaFluticasone/Vilanterol55$25,062
OxycontinOxycodone Hcl22$20,991
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr41$19,132
TrulicityDulaglutide16$16,966
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog37$16,628
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,334
Lantus SolostarInsulin Glargine,hum.Rec.Anlog88$8,469
Spiriva HandihalerTiotropium Bromide14$7,881
Novolog FlexpenInsulin Aspart30$6,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$36$43,29080 claims
AstraZenecaBrilinta$38$5,07612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 981 family medicine providers in Nebraska.

Other family medicine in North Platte

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →